Alexander I. Spira

28.3k citations

506 papers · 9.9k indexed · 8 hit papers · h-index 46

Oncology top 0.2%
- Colorectal Cancer Treatments and Studies 96
- Lung Cancer Research Studies 86
- Cancer Immunotherapy and Biomarkers 83
- HER2/EGFR in Cancer Research 65
- Peptidase Inhibition and Analysis 40
Virology top 1%
Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations 198
Cancer Research top 1%
- Cancer Genomics and Diagnostics 50
Immunology top 2%
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 44

Co-authors: Preston A. Marx D D Ho Steven M. Wolinsky J. Matthew Mahoney Bruce K. Patterson Richard A. Koup Pasi A. Jänne Sai‐Hong Ignatius Ou
Cited by: Oncology Virology Pulmonary and Respiratory Medicine
Partner nations: United States Spain United Kingdom

In The Last Decade

Alexander I. Spira

469 papers receiving 9.8k citations

Hit Papers

8 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2024 Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
2023 Adagrasib in Advanced Solid Tumors Harboring aKRAS^G12CMutation
2022 Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
2022 Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
2015 Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
2015 Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
2008 First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
1996 Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques.

Peers

Countries citing papers authored by Alexander I. Spira

Since Specialization

Citations

This map shows the geographic impact of Alexander I. Spira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander I. Spira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander I. Spira more than expected).

Fields of papers citing papers by Alexander I. Spira

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander I. Spira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander I. Spira. The network helps show where Alexander I. Spira may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alexander I. Spira, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alexander I. Spira Line = papers co-authored together Alexander I. Spira links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC Alexander I. Spira,David Berz,Robert M. Jotte,Krishna Pachipala,Mark S. Berger	2025	0
2	691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation Alison M. Schram,Gilberto Lopes,A.B. El-Khoueiry,Elisa Fontana,Thomas B. Karasic,S. Kummar,Patricia LoRusso,Vanesa Gregorc,M. Millward,S. Ponce Aix,Dominic Richardson,D. Roda Perez,Alexander I. Spira,Daniel Shao-Weng Tan,John A. Thompson,Dipesh Uprety,Marc Fellous,Yanguo Qin,Ecaterina E. Dumbrava	2024	2
3	Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer Shubham Pant,Byoung Chul Cho,Christos E. Kyriakopoulos,Alexander I. Spira,Nizar M. Tannir,Theresa L. Werner,Xiaohong Yan,Saskia Neuteboom,Richard C. Chao,Sanjay Goel	2024	1
4	1000MO A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors Kristopher Wentzel,J. Peguero,S. Kummar,Patricia LoRusso,Janice M. Mehnert,Alexander I. Spira,A. Naing,Omid Hamid,I. Mehmi,Karim A. Benhadji,Leila Alland,Xi Hu,Hong‐Ping Xiao,Xun Bao,Junxi Chen,Yubao Gong,Xuesheng Liu	2024	2
5	1006P Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors M. De Miguel,A. Landa Magdalena,Víctor Moreno,V. Gambardella,Jessica Menis,Giuseppe Daniele,Anthony B. El-Khoueiry,Alexander I. Spira,Alessia Gravina,Anthony J. Olszanski,O. Rapaic,Junhua Li,Hombline Poullain,Germain Margall,G. Wong,William D. Hedrich,Jack Russella Pollard,Jinping Gan,Xiaorong Shi,Robert H.I. Andtbacka	2024	0
6	625P Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications Marwan Fakih,Davendra Sohal,Justin Call,Susanna V. Ulahannan,A.B. El-Khoueiry,Teresa Cenarro Guerrero,Thomas B. Karasic,Alexander I. Spira,Min Zhong,Hanne Merrit,Kishore Hari,Ovidiu C. Trifan,N. Dhawan	2024	2
7	PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) Alexander I. Spira,Byoung Chul Cho,Enriqueta Felip,Edward B. Garon,Kōichi Goto,Melissa Johnson,Natasha B. Leighl,Antonio Passaro,David Planchard,Sanjay Popat,James Chih‐Hsin Yang,Xiaoqian Lu,Yong Jiang,Jack Huang,Morgan Lam,Marcin Kowanetz,Shirley Wang,John T. Le,Jerry Y. Hsu,Caicun Zhou	2024	0
8	742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors Jong Chul Park,David Berz,Manish Sharma,Erminia Massarelli,Ralph J. Hauke,Frank Tsai,David S. Hong,Neal S. Akhave,Justin Call,Jennifer W. Carlisle,Rachel E. Sanborn,Naomi B. Haas,John Hamm,D. Ross Camidge,Alexander I. Spira,Vasily Andrianov,Brianne O’Neill,Heather Kinkead,Anthony W. Tolcher	2023	2
9	756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors Alexander I. Spira,Michael S. Gordon,Jason T. Henry,Sandip Pravin Patel,Kartik Sehgal,Shiraj Sen,Randy F. Sweis,Marsha Crochiere,Shui He,(unknown),(unknown),Bin Zhang,Anthony W. Tolcher	2023	1
10	1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors Sunil Babu,Shunsuke Kondo,N. Ammakkanavar,Alexander I. Spira,Ruth Perets,Toshihiko Doi,Jair Bar,Andrae Vandross,David Sommerhalder,Vladimir Nikolić,Catherine Tribouley,Harisha Atluri,Jung Yong Hong,Amanda Schmidt Paustian,Rachel S. Leibman,John D. Powderly	2023	2
11	1318MO First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC) Julia Rotow,Saiama N. Waqar,K. Papadopoulos,J-Y. Hung,Alexander I. Spira,Hui Gan,Tatsuya Yoshida,C-H.S. Kuo,B. Doger de Spéville,Enriqueta Felip,Kiyotaka Yoh,G. Morrison-Thiele,Randy Robinson,Nandini Rudra-Ganguly,Reem Saab,Byoung Chul Cho	2023	4
12	Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300) Elizabeth Lee,Jordi Rodón,Michael J. Demeure,Dustin A. Deming,Noah Federman,Meredith McKean,Alexander I. Spira,David J. Kwiatkowski,Maen Hussein,Erlinda M. Gordon,David K. Crockett,Kristen N. Ganjoo,Brian Schulte,Lee D. Cranmer,Anita Schmid,Willis H. Navarro,Loretta M. Itri,Gopa Iyer	2023	1
13	Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies Melissa L. Johnson,Anthony B. El-Khoueiry,Navid Hafez,Nehal J. Lakhani,Hirva Mamdani,Jordi Rodón,Rachel E. Sanborn,Javier Garciá Corbacho,Valentina Boni,Mark Stroh,Alison L. Hannah,Song Wang,Henry Castro,Alexander I. Spira	2021	45
14	620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion Eugene Shenderov,G.H.G. Mallesara,Piotr J. Wysocki,Wen Xu,Rodryg Ramlau,Andrew Weickhardt,Jakub Żołnierek,Alexander I. Spira,Anthony M. Joshua,John D. Powderly,Emmanuel S. Antonarakis,S. Jang,Jeanny B. Aragon‐Ching,Jiayu Shen,Channing J. Paller,Nicholas J. Vogelzang,Kirsten Leu,Javier Cortés,Chet Bohac,Iwona Ługowska	2021	21
15	A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia Amer M. Zeidan,Maya Ridinger,Tara L. Lin,Pamela S. Becker,Gary J. Schiller,Prapti A. Patel,Alexander I. Spira,Michaela L. Tsai,Errin Samuëlsz,Sandra Silberman,Mark G. Erlander,Eunice S. Wang	2020	57
16	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors Rastislav Bahleda,Antoîne Italiano,Cinta Hierro,Alain C. Mita,Andrés Cervantes,Nancy Chan,Mark M. Awad,Emiliano Calvo,Víctor Moreno,Ramaswamy Govindan,Alexander I. Spira,Martha Gonzalez,Bob Zhong,Ademi Santiago-Walker,Italo Poggesi,Trilok Parekh,Hong Xie,Jeffrey R. Infante,Josep Tabernero	2019	187
17	Detection of NRG1 Gene Fusions in Solid Tumors Sushma Jonna,Rebecca Feldman,Jeffrey Swensen,Zoran Gatalica,W. Michael Korn,Hossein Borghaei,C. Patrick,Jorge J. Nieva,Alexander I. Spira,Ari M. Vanderwalde,Antoinette J. Wozniak,Edward S. Kim,Stephen V. Liu	2019	155
18	Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy Ticiana Leal,Alexander I. Spira,Collin M. Blakely,Kai He,David Berz,Donald Richards,James Uyeki,Abigail L. Savage,Tatiane Roque,Erminia Massarelli,Robert M. Jotte,I. Chen,James G. Christensen,Peter Olson,Vanessa Tassell,Leora Horn	2018	9
19	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations Helena A. Yu,Alexander I. Spira,Leora Horn,Jared Weiss,Howard West,Giuseppe Giaccone,Tracey L. Evans,Ronan J. Kelly,Bhardwaj Desai,Andrew Krivoshik,Diarmuid Moran,Srinivasu Poondru,Fei Jie,Kouji Aoyama,Anne Keating,Geoffrey R. Oxnard	2017	23
20	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trialbreakdown → George D. Demetri,Margaret von Mehren,Robin L. Jones,Martee L. Hensley,Scott M. Schuetze,Arthur P. Staddon,Mohammed Milhem,A. Elias,Kristen N. Ganjoo,Hussein A. Tawbi,Brian Andrew Van Tine,Alexander I. Spira,Andrew Dean,Nushmia Z. Khokhar,Youn Choi Park,Roland E. Knoblauch,Trilok Parekh,Robert G. Maki,Shreyaskumar Patel	2015	576

About Alexander I. Spira

Alexander I. Spira is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 506 papers that have together received 9.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (198 papers), Colorectal Cancer Treatments and Studies (96 papers), Lung Cancer Research Studies (86 papers), Cancer Immunotherapy and Biomarkers (83 papers), HER2/EGFR in Cancer Research (65 papers), Cancer Genomics and Diagnostics (50 papers), Monoclonal and Polyclonal Antibodies Research (44 papers) and Peptidase Inhibition and Analysis (40 papers). The work is most often cited by research in Oncology (5.9k citations), Virology (718 citations) and Pulmonary and Respiratory Medicine (4.6k citations). Alexander I. Spira has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Preston A. Marx, D D Ho, Steven M. Wolinsky, J. Matthew Mahoney, Bruce K. Patterson, Richard A. Koup, Pasi A. Jänne, Sai‐Hong Ignatius Ou, Karen Velastegui and David R. Spigel.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact